Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications

被引:250
作者
Bierhaus, A. [1 ]
Nawroth, P. P. [1 ]
机构
[1] Heidelberg Univ, Dept Med & Clin Chem 1, D-69120 Heidelberg, Germany
关键词
AGE; Diabetes; Glycation; HMGB1; Inflammation; Innate immunity; NF-kappa B; RAGE; Review; S100; GLYCATION END-PRODUCTS; ALTERS ANTIOXIDANT DEFENSES; CELL-SURFACE RECEPTOR; MOBILITY GROUP BOX-1; NF-KAPPA-B; SOLUBLE RECEPTOR; SERUM-LEVELS; CYTOPLASMIC DOMAIN; MODIFIED PROTEINS; ENDPRODUCTS RAGE;
D O I
10.1007/s00125-009-1458-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The pattern recognition receptor or receptor for AGE (RAGE) is constitutionally expressed in a few cell types only. However in almost all cells studied so far it is induced by reactions known to initiate inflammation. Its biological activity seems to be mainly dependent on the presence of its various ligands, including AGE, S100-calcium binding protein/calgranulins, high-mobility group protein 1, amyloid-beta-peptides and the family of beta-sheet fibrils, all known to be elevated in chronic metabolic, malignant and inflammatory diseases. The RAGE pathway interacts with cytokine-, lipopolysaccharide-, oxidised LDL-and glucose-triggered cellular reactions by turning a short-lasting inflammatory response into a sustained change of cellular function driven by perpetuated activation of the proinflammatory transcription factor, nuclear factor kappaB. RAGE-mediated persistent cell activation is of pivotal importance in various experimental and clinical settings, including diabetes and its complications, neurodegeneration, ageing, tumour growth, and autoimmune and infectious inflammatory disease. Due to RAGE's central role in maintaining perpetuated cell activation, various therapeutic attempts to block RAGE or its ligands are currently under investigation. Despite broad experimental evidence for the role of RAGE in chronic disease, knowledge of its physiological function is still missing, limiting predictions about safety of long-term inhibition of RAGE x ligand interaction in chronic diseases.
引用
收藏
页码:2251 / 2263
页数:13
相关论文
共 106 条
[71]   De-N-glycosylation or G82S mutation of RAGE sensitizes its interaction with advanced glycation endproducts [J].
Osawa, Marl ;
Yamamoto, Yasuhiko ;
Munesue, Sefichl ;
Murakami, Naho ;
Sakurai, Shigeru ;
Watanabe, Takuo ;
Yonekura, Hideto ;
Uchigata, Yasuko ;
Iwamoto, Yasuhiko ;
Yamamoto, Hiroshi .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2007, 1770 (10) :1468-1474
[72]   Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts [J].
Park', L ;
Raman, KG ;
Lee, KJ ;
Lu, Y ;
Ferran, LJ ;
Chow, WS ;
Stern, D ;
Schmidt, AM .
NATURE MEDICINE, 1998, 4 (09) :1025-1031
[73]   Polymorphisms of the Receptor of Advanced Glycation Endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients [J].
Prevost, G ;
Fajardy, I ;
Besmond, C ;
Balkau, B ;
Tichet, J ;
Fontaine, P ;
Danze, PM ;
Marre, M .
DIABETES & METABOLISM, 2005, 31 (01) :35-39
[74]   Soluble receptor for advanced glycation end products triggers a proinflammatory cytokine cascade via ß2 integrin Mac-1 [J].
Pullerits, Rille ;
Brisslert, Mikael ;
Jonsson, Ing-Marie ;
Tarkowski, Andrej .
ARTHRITIS AND RHEUMATISM, 2006, 54 (12) :3898-3907
[75]   A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10) [J].
Raucci, Angela ;
Cugusi, Simona ;
Antonelli, Antonella ;
Barabino, Silvia M. ;
Monti, Lucilla ;
Bierhaus, Angelika ;
Reiss, Karina ;
Saftig, Paul ;
Bianchi, Marco E. .
FASEB JOURNAL, 2008, 22 (10) :3716-3727
[76]  
RITTHALER U, 1995, AM J PATHOL, V146, P688
[77]   A 63bp deletion in the promoter of RAGE correlates with a decreased risk for nephropathy in patients with type 2 diabetes [J].
Rudofsky, G ;
Isermann, B ;
Schilling, T ;
Schiekofer, S ;
Andrassy, M ;
Schneider, JG ;
Morcos, M ;
Humpert, PM ;
Sayed, AAR ;
Witte, S ;
Renn, W ;
Pfohl, M ;
Hamann, A ;
Nosikov, V ;
Schleicher, E ;
Häring, HU ;
Rudofsky, G ;
Ritz, E ;
Nawroth, PP ;
Bierhaus, A .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2004, 112 (03) :135-141
[78]   Central role of RAGE-dependent neointimal expansion in arterial restenosis [J].
Sakaguchi, T ;
Yan, SF ;
Du Yan, S ;
Belov, D ;
Rong, LL ;
Sousa, M ;
Andrassy, M ;
Marso, SP ;
Duda, S ;
Arnold, B ;
Liliensiek, B ;
Nawroth, PP ;
Stern, DM ;
Schmidt, AM ;
Naka, Y .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (07) :959-972
[79]   Decreased plasma soluble RAGE in patients with hypercholesterolemia:: Effects of statins [J].
Santilli, Francesca ;
Bucciarelli, Loredana ;
Noto, Davide ;
Cefalu, Angelo B. ;
Davi, Valentina ;
Ferrante, Elisabetta ;
Pettinella, Caterina ;
Averna, Maurizio R. ;
Ciabattoni, Giovanni ;
Davi, Giovanni .
FREE RADICAL BIOLOGY AND MEDICINE, 2007, 43 (09) :1255-1262
[80]   Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications [J].
Santilli, Francesca ;
Vazzana, Natale ;
Bucciarelli, Loredana G. ;
Davi, Giovanni .
CURRENT MEDICINAL CHEMISTRY, 2009, 16 (08) :940-952